Thermo Fisher Scientific 8-K
PositiveEarningsGuidance deferred to the call
Acquisitions and currency drove most revenue growth; the Clario acquisition closed.
Filed 2026-04-23 06:03 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q1 2026 results with updated FY2026 guidance to be provided on the earnings call. Revenue rose 6%, while organic revenue growth was 1%; acquisitions contributed 3 percentage points and currency translation 2 points.
Key Figures
| Metric | Q1 2026 | Q1 2025 | Y/Y |
|---|---|---|---|
| Revenue | $11.0B | $10.4B | 6% |
| Operating income | $1.86B | $1.72B | 9% |
| Adjusted operating income (non-GAAP) | $2.40B | $2.27B | 6% |
| Net income attributable to Thermo Fisher Scientific Inc. | $1.65B | $1.51B | 10% |
| Adjusted net income (non-GAAP) | $2.03B | $1.95B | 4% |
| Diluted EPS | $4.43 | $3.98 | 11% |
| Adjusted EPS (non-GAAP) | $5.44 | $5.15 | 6% |
| Operating cash flow | $1.19B | $723M | 65% |
| Free cash flow (non-GAAP) | $825M | $373M | 121% |
- Organic revenue growth was 1%; acquisitions contributed 3 percentage points and currency translation 2 points to reported revenue growth of 6%.
- GAAP operating margin rose to 16.9% from 16.6% (+30 bp); adjusted operating margin was 21.8% vs 21.9% (-10 bp).
- Completed the Clario acquisition, with $8.87B of net cash used for acquisitions. Repurchased $3.0B of stock vs $2.0B a year earlier; weighted-average diluted shares declined to 373M from 379M. The dividend increased 10%. Cash and cash equivalents were $3.25B at quarter-end vs $9.85B at year-end.
Guidance
Guidance to be given on the earnings call.
Investor Takeaways
- Updated FY2026 guidance on the 4/23/2026 call will provide the next outlook against Q1’s 1% organic revenue growth.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3